Peer-Reviewed Publication
Invest New Drugs2026July 7, 2026Journal Article
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Daruka Mahadevan1, Jay Parekh1, Joseph T Beck2, Willam B McKean3, Karisa C Schreck4, Anthony J Olszanski5, Misty D Shields6, Vu Phan7, John T Hamm8, Bruce B Bank9, Jianli Zhou10, Marc Chamberlain10, Kishor Bhatia10, Reginald Ewesuedo11
1Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
2Highland Oncology, Springdale, AR, USA.
3The START Center for Cancer Research, Mountain Region, West Valley City, UT, USA.
4Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
5Fox Chase Cancer Center, Philadelphia, PA, USA.
6Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
7Cancer and Blood Specialty Clinic, Los Alamitos, CA, USA.
8Norton Cancer Institute, Louisville, KY, USA.
9Northwest Oncology and Hematology, Rolling Meadows, IL, USA.
10Lantern Pharma Inc., Plano, TX, 75024, USA.
11Lantern Pharma Inc., Plano, TX, 75024, USA. rewesuedo@lanternpharma.com.
Abstract
LP-184 is a novel acylfulvene pro-drug that alkylates DNA after bioactivation by the intracellular oxidoreductase prostaglandin reductase 1 (PTGR1). In preclinical studies, potent growth inhibition has been observed against a wide variety of solid tumor models, particularly those carrying DNA damage repair deficiency. Here, we report results of the first-in-human dose escalation trial of LP-184 in…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans